

Docket No.

296551US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Bertrand TAVITIAN, et al.

SERIAL NO:

10/593,256

GAU:

FILED:

September 18, 2006

EXAMINER:

FOR:

APTAMERS SELECTED FROM LIVE TUMOR CELLS AND THE USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

Norman F. Oblon

Registration No. 24,618

22850

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Surinder Sachar

Registration No. 34,423

SHEET

OF

DEC 1 3 2006 SERIAL NO. ATTY DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Form PTO 1449 (Modified) 296551US0PCT 10/593,256 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Bertrand TAVITIAN, et al. FILING DATE **GROUP** September 18, 2006 **U.S. PATENT DOCUMENTS** FILING DATE **SUB EXAMINER** DOCUMENT CLASS DATE NAME IF APPROPRIATE INITIAL NUMBER **CLASS** 5 580 737 12/03/96 POLISKY, Barry et al. AA 2003/049644 03/13/03 RABIN, ROSS et al. AB 08/28/01 PARMA, David H. et al. AC 6 280 932 AD ΑE AF AG AΗ ΑI AJ ΑK AL AM ΑN FOREIGN PATENT DOCUMENTS **TRANSLATION DOCUMENT** DATE COUNTRY NUMBER NO YES AO 2004/011680 02/05/04 WO NO 10/14/99 wo NO ΑP 99/51777 AQ AR AS AT ΑU ΑV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) ICHIHARA, Masatoshi et al., "RET and neuroendocrine tumors", Cancer Letters, Vol. 204, No. 2, Pages 197-211, 2004. AW CHEN, Chi-hong B, et al., "Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3", Proceedings of The National Academy of Sciences of The United States of AX America, Vol. 100, No. 16, Pages 9226-9231, 2003. AY AZ. Additional References sheet(s) attached Date Considered Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.